The Obesity Market Size was USD 1,052 Million in 2021

Obesity market is expected to grow significantly owing to an increase in upcoming novel treatment options, increasing market size due to increasing prevalence, increasing global healthcare investment and funding.

The Obesity market report provides current treatment practices, emerging drugs, Obesity market share of the individual therapies, current and forecasted obesity market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Obesity Market Research Report

• According to the DelveInsight's analyst, the diagnosed prevalent cases of Obesity are on the rise, and as per DelveInsight's estimates, the United States accounted for ~112,251,200 and 5,201,300 cases for adults (19 years) and children (5-19 years), respectively in 2022.

• The leading Obesity Companies includes Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.

• Promising Obesity Pipeline Therapies includes Xenical (orlistat), QSYMIA (phentermine/topiramate), CONTRAVE (naltrexon/bupropion), SAXENDA (liraglutide), WEGOVY (semaglutide), IMCIVREE (setmelanotide), Tirzepatide, Oral semaglutide, CagriSema (NNC-0174-0833), Danuglipron (PF-06882961), and others.

To discover which therapies are expected to grab the major Obesity Market share, click here for Obesity Market Research Report @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Obesity Treatment Landscape

• Oral semaglutide is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and Japan under the trade name, RYBELSUS. It is an oral GLP-1 RA, an analogue of the naturally occurring hormone GLP-1. Currently, the company is developing the candidate for obesity. The candidate is being evaluated in Phase III trial (NCT05035095; OASIS 1) to assess the safety and efficacy of the drug in subjects with overweight or obesity. The study is anticipated to be complete by March 2023.

Obesity Overview

Obesity is recognized as a chronic or non-communicable disease, which is a complex, multifactorial phenotype, affecting, along with overweight, primarily associated with excess adiposity, or body fatness which can manifest metabolically and not just with respect to the size of the body.

Obesity Epidemiology Segmentation in the 7MM
• Total Obesity Prevalent Cases
• Total Obesity Treated Cases
• Total Obesity Patients Seeking Help

Download the report to understand which factors are driving Obesity Market Trends, click here for Obesity Market Forecast @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Obesity Market Insights

With the increase in the prevalence of obesity cases around the globe, it has become a major health concern that warrants the development of new therapeutic options for its treatment and management. Because obesity is one of the leading causes of death worldwide, there is tremendous potential for the players engaged in the obesity treatment landscape. There are more effective medications, procedures and evidence-based treatment available for obesity today than 20 years ago, but health care professionals are still struggling to get treatment to more people. Obesity treatment in general is very challenging, in part because it's often not covered by payers. Up until 2003, Medicare had an explicit policy that said you could not consider obesity as a disease or a health condition. It was considered a cosmetic issue; it was explicitly excluded from any kind of Medicare treatment.

Obesity Market Dynamics

The dynamics of the weight management in obese and overweight population is anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapies for the management of this issue. Key players, such as Novo Nordisk, Eli and Lilly Company, Pfizer, and others are involved in developing novel therapies for, Overweight and Obesity which will eventually help in the weight management.

To learn more about the Obesity FDA-approved drugs, click here for Obesity Treatment Market @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Obesity Market Report Scope

• Coverage- 7MM

• Obesity Companies- Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.

• Obesity Pipeline Therapies- Xenical (orlistat), QSYMIA (phentermine/topiramate), CONTRAVE (naltrexon/bupropion), SAXENDA (liraglutide), WEGOVY (semaglutide), IMCIVREE (setmelanotide), Tirzepatide, Oral semaglutide, CagriSema (NNC-0174-0833), Danuglipron (PF-06882961), and others.

• Obesity Market Dynamics: Obesity Market Drivers and Barriers

To discover more about Obesity Drugs in development, click here for Obesity Market Drugs @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Obesity Market Overview at a Glance
4. Key Events
5. Epidemiology and Market Methodology
6. Disease Background and Overview
7. Obesity Diagnosis
8. Treatment and Management
9. Epidemiology and Patient Population
10. Obesity: Country-wise Epidemiology
11. Patient Journey
12. Obesity Marketed Therapies
13. Emerging Obesity Therapies
14. Conjoint Analysis
15. Obesity: 7 Major Market Analysis
16. Reimbursement and Market access
17. KOL Views
18. Obesity Market Drivers
19. Obesity Market Barriers
20. SWOT Analysis
21. Unmet Needs
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight

To read more about the Obesity Market Dynamics of the report, click here for Obesity Market Barriers and Drivers @ https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.